Dystrophin is a rod-shaped cytoskeletal protein that connects the intercellular cytoskeleton to the extracellular matrix through an actin-associated glycoprotein complex. This property enables Dystrophin to play a role in sarcolemmal stability during muscle contraction and prevent contraction damage. Dystrophin also mediates cell signaling, such as mechanotransduction and cell adhesion. However, Dystrophin deficiency or mutation (producing internally truncated Dystrophin) will become a predisposing factor for Duchenne muscular dystrophy (DMD). In the muscle tissue of mild and asymptomatic patients, a large number of alternative Dystrophin splicing protein products can be detected. Currently, the methods for restoring Dystrophin mutations rely on virus-mediated restoration or exon skipping. Exon skipping uses antisense oligonucleotides to induce alternative splicing, bypassing the mutated exon to restore the protein reading frame, and converting DMD mutations to Becker muscular dystrophy (BMD) protein mutations.
Dystrophin-related proteins can be divided into three groups (according to subcellular localization): (1) α-dystroglycan located outside the cell; (2) β-dystroglycan, sarcoglycans, and sarcospan located on the plasma membrane; (3) Dystrophin, dystrobrevin, syntrophins, and neuronal nitric oxide synthase located inside the cell. Dystrophin has four major functional domains: the actin-binding amino-terminal domain (ABD1), the central rod domain, the cysteine-rich domain, and the carboxyl terminus. Dystrophin interacts with tubulin and acidic actin filaments through the rod domain, so Dystrophin mutations not only lead to progressive loss of muscle tissue and function, but also cause cardiomyopathy[1][2][3].
ARC19499 是一种核酸适配体,能特异性结合组织因子通路抑制剂(TFPI),阻断 TFPI 对 factor Xa 和 TF/factor VIIa 复合物的抑制作用,从而纠正血友病 A 和 B 血浆中的凝血酶生成并恢复凝血。
ARC19499 sodium 是一种核酸适配体,与组织因子通路抑制剂(TFPI)特异性结合,阻断 TFPI 对 factor Xa 和 TF/factor VIIa 复合物的抑制作用,从而纠正血友病 A 和 B 血浆中的凝血酶生成并恢复凝血。
ARC19499 sodium scrambled negative control 是 ARC19499 sodium 的乱序阴性对照。
Befovacimab (BAY 1093884) 是一种能够结合组织因子通路抑制剂 (TFPI) 的全人源单克隆 IgG2 抗体,可用于血友病 A/B 的研究。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号